In:
Therapeutic Advances in Medical Oncology, SAGE Publications, Vol. 11 ( 2019-01), p. 175883591987801-
Kurzfassung:
Langerhans cell histiocytosis (LCH) is a diagnostic and therapeutic challenge. We report on a rare case of its primary oral manifestation that was treated successfully with the BRAF-specific agent, vemurafenib, after insufficient standard LCH treatment. This case underlines the importance of proper diagnosis and the evaluation of targeted therapy as a valuable tool in LCH treatment. Furthermore, the close collaboration of surgeons, oncologists, and dentists is mandatory to ensure adequate treatment, restore the stomatognathic system in debilitating post-treatment situations, improve quality of life, and ensure effective disease control in infants and young patients.
Materialart:
Online-Ressource
ISSN:
1758-8359
,
1758-8359
DOI:
10.1177/1758835919878013
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2019
ZDB Id:
2503443-1
Permalink